Table 1.
Demographic and clinical data of patients. Values are given as median (range). (Normal values: CK women < 2.41 mmol / L*s, men <2.81 mmol / L*s, eosinophils <5%.) * Kruskal-Wallis One Way Analysis of Variance on Ranks, post hoc analysis using Dunn's method, n.a. not applicable
| Disease | Number (n) | Gender (F/M) | Age at biopsy (years) | Disase duration (years) | Creatine kinase (μmol/L*s) | Increased eosinophil count in haemogram (n) |
|---|---|---|---|---|---|---|
| Hereditary myopathies | ||||||
| LGMD2A | 12 | 4/8 | 30 (10-72) | 7 (2-49) |
8.3 (2.5-349) |
1/7 |
| LGMD2B | 4 | 2/2 | 43 (34-52) |
20 (6-22) |
67 (38-123) |
0/4 |
| LGMD2L | 3 | 1/2 | 49 (29-69) |
6 (5-24) |
37 (22-74) |
0/3 |
| FSHD | 5 | 5/0 | 39 (21-71) |
8(1-19) | 2.2 (2-12) |
1/3 |
| DMD/BMD | 8 | 0/8 | 11 (3-21) |
3(1-13) | 81 (18-293) |
0/3 |
| Idiopathic inflammatory myopathies | ||||||
| DM | 11 | 5/6 | 54 (15-84) |
0.5 (0.1-10) |
8.6 (0.7-227) |
1/6 |
| PM | 13 | 7/6 | 54 (32-77) |
1.0 (0.3-6) |
15 (0.9-112) |
0/12 |
| sIBM | 10 | 5/5 | 70 (52-77) |
3 (1-10) |
9.4 (2-17) |
1/7 |
| Neurogenic control | ||||||
| ALS | 11 | 6/5 | 47 (35-72) |
1 (0.3-4) |
8.2 (2-24) |
1/7 |
| Normal control# | 24 | 13/11 | 5236 (24-75) |
n.a. | 1.98 (0.6-2.8) |
0/8 |
| p* | <0.0001 | <0.0002 | 0.0023 |
The normal controls were defined as having myalgia and exertion-induced complaints but no paresis or muscle atrophy, normal creatine kinase levels, normal EMG, and only mild unspecific changes or normal features in muscle biopsy. * Kruskal-Wallis One Way Analysis of Variance on Ranks, , post hoc analysis using Dunn's method, n.a. not applicable ALS amyotrophic lateral sclerosis, BMD muscular dystrophy Becker type, DM dermatomyositis, DMD muscular dystrophy Duchenne type, LGMD limb girdle muscular dystrophy, PM polymyositis, sIBM sporadic inclusion body myositis
post hoc analysis:
sIBM, DM, PM vs. DMD/BMD p<0.05, sIBM vs. LGMD2A, controls;
DM vs. LGMD2A, LGMD2B, LGMD2L,
controls vs. DMD/BMD, LGMD2A, LGMD2B, LGMD2L p<0.05.